Some new vascular and biochemical aspects of the mechanism of action of ergot compounds.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D004285:Dogs; D004877:Ergoloid Mesylates / Q000494:pharmacology; D004876:Ergot Alkaloids / Q000494:pharmacology*; D004878:Ergotamine / Q000494:pharmacology; D008881:Migraine Disorders / Q000188:drug therapy*; D009417:Nerve Tissue / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism*; D010643:Phenoxybenzamine / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects*; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents
D000317:Adrenergic alpha-Antagonists; D004876:Ergot Alkaloids; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D004877:Ergoloid Mesylates; D004878:Ergotamine; D009638:Norepinephrine